Vical (NASDAQ: VICL) and TESARO (NASDAQ:TSRO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.
Insider & Institutional Ownership
16.5% of Vical shares are held by institutional investors. 6.0% of Vical shares are held by insiders. Comparatively, 34.6% of TESARO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Vical has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, TESARO has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Vical and TESARO, as provided by MarketBeat.com.
||Strong Buy Ratings
Vical presently has a consensus target price of $7.00, indicating a potential upside of 376.19%. TESARO has a consensus target price of $148.74, indicating a potential upside of 147.90%. Given Vical’s stronger consensus rating and higher possible upside, research analysts clearly believe Vical is more favorable than TESARO.
This table compares Vical and TESARO’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Vical and TESARO’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Vical has higher earnings, but lower revenue than TESARO. TESARO is trading at a lower price-to-earnings ratio than Vical, indicating that it is currently the more affordable of the two stocks.
Vical beats TESARO on 9 of the 13 factors compared between the two stocks.
Vical Company Profile
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
TESARO Company Profile
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.